

ArcticZymes Technologies launches T7 RNA Polymerase

Tromsø, Norway, December 21, 2023 – ArcticZymes Technologies ASA (OSE: AZT) launches T7 RNA Polymerase

ArcticZymes Technologies (AZT) today announces the launch of its new product, T7 RNA Polymerase. Serving customers within the Molecular Tools segment, the T7 RNA Polymerase is intended for use in molecular research and diagnostics. The enzyme precedes the planned launch of a bioprocessing grade T7 RNA polymerase scheduled for 2024.

The launch of the T7 RNA Polymerase is an example of ArcticZymes exploiting synergies between its business segments. While the field of RNA therapeutics is rapidly evolving, the T7 RNA Polymerase may support different research areas as well as being a key component in various molecular diagnostic applications.

The T7 RNA Polymerase will be available for ordering during January 2024.

CEO, Michael B. Akoh said: *“The launch of ArcticZymes T7 RNA Polymerase is an important addition to our expanding Molecular Tools portfolio. Moreover, it is the first of a portfolio of RNA enzymes that will allow us to tap into a growing market for RNA therapeutics.”*

For more information, please contact:

CEO, Michael Akoh

Tel: +46 70 262 37 15

CFO, Børge Sørvoll

Tel: +47 952 90187
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

The company is listed on the Oslo Stock Exchange since 2005 as ArcticZymes Technologies under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents. For more information, please visit the website: www.arcticzymes.com